Which hedge funds own ANTX? AN2 THERAPEUTICS INC, Q2 2026 13F holders
21 tracked hedge funds disclosed a position in ANTX (AN2 THERAPEUTICS INC) in their Q2 2026 13F filings, worth $74.7m in total. The largest holder by portfolio weight is Ally Bridge Group (NY) LLC at 3.3% of its book. 5 opened a new position this quarter: SummitTX Capital, L.P., Bronte Capital Management Pty Ltd., Balyasny Asset Management L.P., Walleye Capital LLC. 5 exited: Persistent Asset Partners Ltd, Centiva Capital, LP, Hudson Bay Capital Management LP.
- 21
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 5
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 5
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $6.1m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $649k
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $74.7m
- Combined value Sum of the holders' reported positions in the security.
- 1.7%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Persistent Asset Partners Ltd | 0.05% | $130k |
| Centiva Capital, LP | 0.01% | $257k |
| Hudson Bay Capital Management LP | 0.0% | $118k |
| Qube Research & Technologies Ltd | 0.0% | $82.7k |
| Marshall Wace, LLP | 0.0% | $60.5k |
Ownership over time
Who discovered ANTX first? Beta
The run: Q2 2025 → Q3 2026, +402%
| Stonepine Capital Management, LLC | Q1 2026 | 0.6% | +2.1 pts |
| Almitas Capital LLC | Q1 2026 | 0.4% | +1.1 pts |
| BML Capital Management, LLC high conviction | Q3 2024 | 6.3% | +1.0 pts |
| Ally Bridge Group (NY) LLC | Q1 2026 | – | +0.7 pts |
| Spruce Street Capital LP | Q1 2026 | – | +0.6 pts |
| Octagon Capital Advisors LP | Q3 2023 | – | −0.5 pts |
| Frazier Life Sciences Management, L.P. | Q3 2023 | – | −0.9 pts |
| RA Capital Management, L.P. | Q1 2022 | – | −1.0 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.